Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for June 2007
June 1, 2007
- Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
- Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
- EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
- Waismann Method Survey Reveals Dependency Risk for People Using Suboxone
- Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
- World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
- Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
- Top Line Results of Phase III Study in Acute Ischemic Stroke (DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
- Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
- ISTA Pharmaceuticals Announces Positive Preliminary Results from Ecabet Sodium Phase IIb Study
- Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
- CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007
- CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
- Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
- Oncolytics Biotech Inc.'s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
- Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
- Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
- Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
- Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
- Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
- OXiGENE Abstracts Published in ASCO Program
June 4, 2007
- AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
- SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
- MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
- Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
- Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
- Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
- Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
- Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
- Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
- GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
- New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting
- Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
- Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
- Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
- Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
- ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
- Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
- Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
- Cardiome And Astellas Announce Positive Results From ACT 2 Trial
- Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
- Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
- Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
- Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
- Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
- Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
- Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
- New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
- Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
- Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
- Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
- Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
- Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
- Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
- The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
- Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
- Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
- Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
- Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
- New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
- Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment
- Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
- Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
- ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
- Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
- Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
- Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
- Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
- Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
- Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
- Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
- Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
- Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine
- Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
- News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
- Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer - Jun 4, 2007
- Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA Nanoparticles
- Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
- GSK'S Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
- 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
- Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
- New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
June 5, 2007
- NovaDel Announces Positive Data from Two Studies Comparing Zolpidem Oral Spray to Ambien Tablets
- XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
- Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO
- Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
- Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
- Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
- Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival - Jun 5, 2007
- Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
- New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
- New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE) in Combination and as a Single Agent for the Treatment of Lung and Ovarian Cancers
- MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
- Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
- Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
- OSI Pharmaceuticals Summarizes Data on Tarceva (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
- Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
- Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
- Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
- MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
- ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
- Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
- Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
- Synta Pharmaceuticals to Host Conference Call Today
- Encouraging Clinical Activity of GSK's Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
- IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
- Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine) Clinical Data at the Annual NCDEU Meeting
- Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
- Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
- Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
- Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
- Cogane Data Presented at ‘11th International Congress of Parkinson’s Disease and Disorders’
- Theratechnologies: TH9507 Phase 3 Clinical Update
- Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
- Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
- Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
- Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
- Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
- Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
June 6, 2007
- Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
- Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
- Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
- XTL Provides Update on Phase I Clinical Trial of XTL-2125
- Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
- Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimer's Disease Study
- Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease Presented at International Congress of Parkinson's Disease and Movement Disorders
- MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the American Headache Society Meeting
- Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
- Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
- Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
- Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
- Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
- Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Society's Annual Meeting
- New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
June 7, 2007
- OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
- Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
- Dynogen Reports Positive Results in Phase 1B GERD Study
- Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
- Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
- Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
- Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress
- Indevus Reports Positive Data From Phase III NEBIDO Trial
- Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
- Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
- Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's AAGP
- Prana Biotechnology Presents New Key Findings on PBT2
- Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology
- To Stent or Not: Is That the Question?
- NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
- Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study
June 8, 2007
- Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
- ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
- Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease
- AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
- International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinson's Disease
- Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
- Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
- Archemix Announces Completion of Phase 1 Trial of ARC1779
- Eurand to Present Zentase Phase III Data
- Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
- NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine
- ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at American Headache Society Meeting
- Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
- IMPAX Presents at Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders
June 11, 2007
- Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
- Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
- Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
- Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study
- Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
- Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
- Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression
- Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
- Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
- Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
- Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
- Medivation's Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy
- Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
- Karo Bio Announces Sucessfule Phase II Results of KB2115
- Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients
- Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease
- Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
- At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
- Data Showing that ReGen's Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
- Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA
- Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
- Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
- Gabapentin Shown Effective for Fibromyalgia Pain
- NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
June 12, 2007
- Inspire Announces Presentations at Two European Scientific Conferences
- Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
- Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
- Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimer's Disease at International Conference on Prevention of Dementia
- Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
- Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
- Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
- Ivivi's PEMF Technology Significantly Improves Neuron Survival in Parkinson's Disease Model, Study Finds
- July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
- Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
- CuraGen Presents Update on Clinical Development Program for Belinostat
- Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
- Women Well-Informed About Breast Cancer, Yet Lacking Knowledge About Current Treatments, New Survey Finds
June 13, 2007
- Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
- Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
- Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
- EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3 Clinical Trial at 47th Annual NCDEU Meeting
June 14, 2007
- Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease
- Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
- Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
- Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
- Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
- Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
- Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
- Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
- Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
- Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
- Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
- Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study
- Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
- Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
- Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
- PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
- Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
June 15, 2007
- Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
- Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
- Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
- New Positive Pre-clinical Data for Active Biotech's RA Project I-3D
- GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
- Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
- Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
- Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
- Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
- Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
- Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
- New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
- Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
June 18, 2007
- New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
- Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
- VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
- Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
- Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
- Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
- Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
- Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
- Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
- BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
- First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
June 19, 2007
- Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
- Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
- New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
- Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
- Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
- Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
- Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
- Clot-dissolving Agent May Be Beneficial in Treatment of Severe Frostbite
- Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
- Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
- Eurand's Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
- New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes
- New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
June 20, 2007
- Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
- First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
- Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
- Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
- Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
- Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
- Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
- Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
- ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
- Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
- Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
- President Bush Ignores America's Plea for Support of Stem Cell Research
- Materia Licenses Metathesis Catalyst Platform to Eisai
- Researchers Discover Gene For Rare Skin Disorder
- Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
- Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
- SemBioSys to present new data at American Diabetes Association annual meeting
- The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bush's Veto of the Stem Cell Research Enhancement Act
- Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
- Dean: President Bush Has Turned His Back on the American People
June 21, 2007
- Apollo's human proteins boost stem cell research
- New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
- Pharmexa A/S (DK) - Pharmexa presents data from influenza program
- Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
- New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
- Diabetes drug supported by Mexican Diabetes Federation
- Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Women's Health Initiative Data
- Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
- Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
- Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
- Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
- Obama Statement on Bush Veto of Stem Cell Bill
- Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
- Remarks by President Bush on Stem Cell Veto and Executive Order
- Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
- Pelosi: Bush Veto of Stem Cell Bill Says 'No' to the Hopes of Million of Families Across America
- Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
- Nationwide MRSA Prevalence Study to Demonstrate Full Scope of 'Superbug' Threat Facing U.S. Healthcare Facilities and Patients
- Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
- Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
- Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
- Malvern initiates European user group meetings for chemical imaging
- AMIA Announces 2008 Summit on Translational Bioinformatics
- PromegaExpress Expands Easy Access to Products with New Cabinet
- MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
- Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
June 22, 2007
- MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
- deCODE Biostructures, Inc. Initiates New Research Collaboration with Genus Onocology, LLC
- Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
- Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease
- MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
- GenoLogics Announces Bioinformatics Partnership with Illumina
June 25, 2007
- Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
- Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
- Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting
- Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
- DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
- Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
- VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
- BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
- New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
- Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
- Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
- New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
- Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
- Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
- Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
- CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
- Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
- Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
- Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
- Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
- Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
- Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
- New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
- Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
- Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology
- HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
- Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
- Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
- First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
- Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
- New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
- MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
June 26, 2007
- Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
- SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
- Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
- Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
- Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
- ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
- An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
- Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease
- Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
- Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
- Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
- Genetics Journal Thimerosal/Autism Study the 'Best Science Drug Company Money Can Buy'
- Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
June 27, 2007
- New Proof of Genistein's Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
- Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
- Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
- Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
- CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
- In Vitro and In Vivo Data Show Alfacell's Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
- Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
- Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
- Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
- Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
- Gentium's Defibrotide Seen as Active in Multiple Myeloma
- Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
- Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
June 28, 2007
- A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
- Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
- Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
- New Study Shows Hib Vaccine Protects Children From Significant Burden of Life-Threatening Pneumonia and Meningitis
- ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
- CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
- Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
- Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
- Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
- Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
- Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
- Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
- Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
- Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
June 29, 2007
- Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Children's Hospital and Stanford
- The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
- New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
- The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
- Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
- Biotec Pharmacon Announces Preliminary Results from the Sloan-Kettering Clinical Study
- Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
- European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGene's Cancer-Killing Virus in Press Conference
- Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
- Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
- RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
- Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycin's First of Two Phase 3 Pneumonia Trials
- Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
